FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Pillar Invest Corp		 2. Issuer Name and Ticker or Trading Symbol

IDERA PHARMACEUTICALS, INC. [ IDRA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

PILLAR INVEST OFFSHORE SAL STARCO CTR,, BLOC B, 3RD FLOOR, OMAR DAOUK STREET		 3. Date of Earliest Transaction (MM/DD/YYYY)

7/13/2020
(Street)

BEIRUT, M8 2020-3313
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 7/13/2020  P  749993 (1)A$1.72 5427697 I By Pillar Partners Foundation, L.P. See Footnotes (1)(2)
Common Stock         21100 I By Pillar Pharmaceuticals I, L.P. See Footnote (2)
Common Stock         20820 I By Pillar Pharmaceuticals II, L.P. See Footnote (2)
Common Stock         29998 I By Pillar Pharmaceuticals III, L.P. See Footnote (2)
Common Stock         1000 I By Pillar Pharmaceuticals IV, L.P. See Footnote (2)
Common Stock         25000 I By Pillar Pharmaceuticals V, L.P. See Footnote (2)
Common Stock         1288368 I By Pillar Pharmaceuticals 6, L.P. See Footnote (2)
Common Stock         6724 I By Youssef El Zein See Footnote (2)
Common Stock         190117 I By Abude Umari See Footnotes (2)(3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Prefunded Warrants  (4)(5)7/13/2020  P   2014234     (4)(5) (4)(5)Common Stock 2014234 $0.00 (4)(5)2014234 I By Pillar Partners Foundation, L.P. See Footnote (2)
Common Warrants  (6)(7)7/13/2020  P   2764227     (6)(7) (6)(7)Common Stock 2764227 $0.00 (6)(7)2764227 I By Pillar Partners Foundation, L.P. See Footnote (2)
Explanation of Responses:
(1) On July 13, 2020, upon the consummation of a private placement of the Issuer (the "Private Placement"), Pillar Partners Foundation, L.P. ("Pillar Foundation"), acquired, in the Private Placement, (i) 749,993 shares of common stock (the "Pillar Foundation Shares") (ii) pre-funded warrants to purchase 2,014,234 shares of common stock of the Issuer (the "Prefunded Warrants") and (iii) warrants to purchase 2,764,267 shares of common stock of the Issuer (the "Common Warrants" and together with the Prefunded Warrants, the "Pillar Foundation Warrants"). The price per share for the Pillar Foundation Shares was $1.72, and the price per Pillar Foundation Warrant was $0.125.
(2) Pillar Invest Corporation ("Pillar GP") is the general partner of Pillar Pharmaceuticals I, L.P., Pillar Pharmaceuticals II, L.P., Pillar Pharmaceuticals III, L.P., Pillar Pharmaceuticals IV, L.P., Pillar Pharmaceuticals V, L.P., Pillar Pharmaceuticals 6, L.P. ("Pillar 6") and Pillar Foundation (collectively, the "Pillar Funds"). Youssef El Zein and Abude Umari are directors of Pillar GP. Each of Pillar GP, Mr. El Zein and Mr. Umari disclaims Section 16 beneficial ownership of the securities beneficially owned by the Pillar Funds and this report shall not be deemed an admission that any of Pillar GP, Mr. El Zein or Mr. Umari is the Section 16 beneficial owner of any such securities, except to the extent of its or his pecuniary interest therein, if any, by virtue of its or his ownership interest in the Pillar Funds or Pillar GP, as applicable.
(3) Includes 103,891 shares received in a prior pro rata, without value distribution from Pillar 6, and 46,304 shares received in a prior pro rata, without value distribution from Pillar Foundation. These distributions were effected in compliance with the exemptions afforded pursuant to Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
(4) The exercise price of each Prefunded Warrant is $0.01 per Share, subject to adjustment pursuant to the terms of the Prefunded Warrants.
(5) The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").
(6) The exercise price of each Common Warrant is $2.58 per share, subject to adjustment pursuant to the terms of the Common Warrants.
(7) The Common Warrants are currently exercisable; provided, however, that the Common Warrants are subject to the Beneficial Ownership Limitation. The Common Warrants expire 3 years following their issuance date.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Pillar Invest Corp
PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

Pillar Partners Foundation, L.P.
PILLAR INVEST OFFSHORE SAL STARCO CTR
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

Umari Abude
PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

ZEIN YOUSSEF EL
PILLAR INVEST OFFSHORE SAL, STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X
Signatures
Pillar Invest Corporation, /s/ Youssef El Zein, Authorized Person7/15/2020
**Signature of Reporting PersonDate

Pillar Partners Foundation, L.P., /s/ Youssef El Zein, Authorized Person7/15/2020
**Signature of Reporting PersonDate

/s/ Abude Umari7/15/2020
**Signature of Reporting PersonDate

/s/ Youssef El Zein7/15/2020
**Signature of Reporting PersonDate
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Idera Pharmaceuticals Charts.
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Idera Pharmaceuticals Charts.